BSX
Boston Scientific Corporation
BSX's fundamentals are strong and it looks cheap: trading at 19x earnings, about a third of its usual 64x. Analysts expect earnings to hold roughly steady.
BSX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Stable |
BSX's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
BSX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $44.20 | — |
| Cheap | 18x | $43.27 | -2.1% |
| Current | 19x | $44.20 | — |
| Fair | 64x | $151 | +241% |
| Expensive | 90x | $211 | +378% |
Historical ranges are pointers, not guarantees.
BSX's PE is in its cheap range at 19x. On analysts' estimates for next year's earnings, today's price would be 14x.
BSX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Moderate | |
| High |
Analysts expect BSX's earnings, revenue and profitability to hold roughly steady.
BSX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.09 | +31% |
| Q3 2026 | $2.36 | +26% |
| Q2 2026 | $2.47 | +47% |
| Q1 2026 | $2.39 | +74% |
| Q4 2025 | $1.94 | +55% |
| Q3 2025 | $1.87 | +55% |
| Q2 2025 | $1.68 | +37% |
| Q1 2025 | $1.37 | +15% |
| Q4 2024 | $1.25 | +17% |
BSX's earnings per share have fallen from their peak: $2.36 over the past year, against $3.33 in late 2019.
BSX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +1.4% |
| Q2 2026 | $5.4B | +7.5% |
| Q1 2026 | $5.2B | +12% |
| Q4 2025 | $5.3B | +16% |
| Q3 2025 | $5.1B | +20% |
| Q2 2025 | $5.1B | +23% |
| Q1 2025 | $4.7B | +21% |
| Q4 2024 | $4.6B | +22% |
BSX's revenue has grown year over year for 23 quarters in a row: $5.1B last quarter, up 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -4.6 points |
| Q2 2026 | 22% | +5.5 points |
| Q1 2026 | 21% | +1.4 points |
| Q4 2025 | 16% | +0.8 points |
| Q3 2025 | 21% | +3.3 points |
| Q2 2025 | 16% | +3.6 points |
| Q1 2025 | 20% | +2.2 points |
| Q4 2024 | 15% | -0.9 points |
BSX's operating margin was 16% last quarter, down 4.6 points from the same quarter a year ago.
BSX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $868M | -25% |
| Q2 2026 | $1.3B | +13% |
| Q1 2026 | $171M | -52% |
| Q4 2025 | $1B | -14% |
| Q3 2025 | $1.2B | +41% |
| Q2 2025 | $1.1B | +72% |
| Q1 2025 | $354M | +$369M |
| Q4 2024 | $1.2B | +71% |
BSX generated $3.3B in free cash flow over the past year, down 13% from the year before.
BSX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -22.8M shares |
| 1 year | -2.9% | -43.5M shares |
| 3 years | -1.6% | -23M shares |
| 5 years | +1.1% | +16.4M shares |
| Available history | +2.9% | +41.4M shares |
BSX has 1.5B diluted shares, down 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
BSX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.7x | Moderate |
BSX's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
BSX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 25.4 | Neutral |
BSX's weekly RSI is 40 (neutral) and its Stochastic is 25 (neutral).
BSX PE vs Healthcare Sector
| Metric | BSX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 17 | 29 | 12 pts below |
BSX is trading at 19x earnings, a 28% discount to the Healthcare sector's median of 26x.
BSX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.5 | 1.5% above |
| 20 week MA | $45.3 | 2.4% below |
| 50 week MA | $60.8 | 27% below |
| 100 week MA | $80.8 | 45% below |
| 200 week MA | $72.2 | 39% below |
BSX has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 39% below its 200-week average.
BSX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $45.2 | $34.6 | -24% |
| 2021 | $34.6 | $42.7 | +24% |
| 2022 | $42.7 | $46.1 | +7.8% |
| 2023 | $46.1 | $57.8 | +26% |
| 2024 | $57.8 | $90.7 | +57% |
| 2025 | $90.7 | $96.1 | +6% |
| 2026 YTD | $96.1 | $44.2 | -54% |
BSX is down 54% so far in 2026, after finishing higher in five of the previous six years.